Slides
Page 1
© 2026 Laurus Labs Ltd. Q2 & H1-FY 2027 Financial Results 29/10/2026 20 Years logo
Page 2
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information fromthis presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same. Safe Harbor Statement 2
Page 3
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 1 Q2 & H1 - FY 2027 Corporate Overview 2 Q2 & H1 - FY 2027 Financial Overview 3 Q2 & H1 - FY 2027 Business Review & Strategy Agenda 3
Page 4
1 Corporate Overview Q2 & H1 FY 2027 4
Page 5
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Executive Summary 5 • Strong H1 performance ; ₹ 4,233 Cr Revenue with 31% growth • Sustained strong growth in CDMO revenue driven by commercial supplies and steady momentum in Affordable Medicines division • ₹ 1,406 Cr EBITDA with margins of 33.2%, increased by 7.8% pts, contributed by higher CDMO revenue and operational leverage • Gross margins expansion of over 3.3% pts to 62.9% on healthy business segment mix • Announced investments in two technology platforms to strengthen Integrated CDMO offering; Oligonucleotides and peptide-resins • CAPEX/Revenue reached 20%, reflecting sustained investment in expanding the manufacturing network and niche capabilities
Page 6
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Strengthen CDMO expertise – Proposed Acquisition Overview • Definitive agreement to acquire 60% stake in Galenvs, specialized in Oligonucleotide and Precision Magnetic Nanoparticles for purification • Expands Laurus position in fast growing Oligo market (+22-24% CAGR) with a North American development footprint • Galenvs early-stage Oligo platform + Laurus large-scale expertise in complex chemistry allows to deliver Integrated service for complex RNA/DNA based therapies • Plans to expand scientific talent in Montreal and manufacturing infrastructure in India Expanding CDMO offering in high growth Oligonucleotide modality Galenvs capabilities Antisense, Aptamers siRNA sgRNA Advance purification incl fill finish Pilot-scale synthesis Market size ~$ 11 bn+ 2030 +22-24% CAGR • Proposed to acquire 52% stake in SI &C Resins, a peptide-resin technology focused company • Expertise with >15 year experience in peptide/polymer chemistry • Ability to develop and manufacture, peptide solid support resins and chromatography stationary phases • Enhanced manufacturing competitiveness and Reliability • Rapid expansion in GLP-1 and non-GLP-1 peptide drugs Enhance Supply chain security and Peptides manufacturing competitiveness Montreal, Canada Hyderabad, India Investments aligns with Laurus strategy to strengthen Integrated scientific capabilities & manufacturing infrastructure
Page 7
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 7 Laurus Peptide CDMO platform and focus on continued capacity expansion Advancing end-to-end Peptide capabilities – Resins, amino acid derivatives, SPPS/LPPS/Purification/Isolation Solid Phase Peptide Synthesis (SPPS) Bio-Ligation Liquid Phase Peptide Synthesis (LPPS) Purification Isolation Commercial API suppliesClinical supplies (Phase I, II and III) Pre-Clinical Peptide Development & Manufacturing Technologies cGMP Pilot facility operational Large-scale peptide manufacturing block operational Peptide team with >250 Scientists FDA and EU inspected facilities SPPS production suite, Vizag Laurus Labs captures entire Value Chain • Linear, cyclic & modified peptides with >16,000 L of Total Reactor Volume with synthesizers up to 2000L • Significant capacity under further expansion • Several large scale manufacturing lines operational • In-house enzyme manufacturing • Multiple DAC systems up to 1200mm dia • Multiple Lyophilizers up to 45 sq. m area • Various types and capacities of Spray drying
Page 8
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation ATR progress (FY21-27*) * Cumulative addition including CWIP, Land, ETP and plant maintenance till September 2026 FY22-27* CAPEX : ₹5180+ Cr (16% of Revenue) Advancing Key CAPEX projects across portfolio and technologies • >85% of Growth CAPEX planned into diversified portfolio with high-growth projects in API, Formulations, Peptides, Fermentation, Gene Therapy and ADCs • Healthy order book, strong internal pipeline, and key customer commitments • H1 CAPEX at ₹ 864 Cr; 20% of Revenue • ATR improving in medium-term in-line with 6 year Long term average H1 CAPEX : ₹864 Cr (20% of Revenue) By Portfolio mix Medium term 6-Yr average 1.1x 8Laurus intends to invest > ₹ 3,000 Cr over FY27 and FY28 across Manufacturing network and Capability expansion 1.4x 1.1x 1.1x 0.8x 0.8x 0.9x 1.0x FY21 FY25 FY26 1H FY27 87% 84% 16% Growth CAPEX API/CDMO FDF 92% 8% API/CDMO FDF
Page 9
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Enzyme Fermentation plant boosting biocatalysis capacity • Commercial scale manufacturing and Future expansion scope (>1.2mn liters) • Precision fermentation and strain engineering Large-scale API facility Unit -7 • Multiple API blocks, Flexible manufacturing • Large-scale API capacity • Future expansion 9 Commercial Gene & ADC platform with fill-finish • One-stop Service platform for complete ADC programs (Payload-linker, Conjugation, Fill-finish) • Commercial-scale capacity Large-scale Peptides API manufacturing • SPPS, LPPS and hybrid approaches + advanced downstream technology • Large scale capacity for GLP & non-GLP programs Key Growth investment projects – Enhancing broadest capability offering 1 2 3 4
Page 10
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Unit 1 & 3, Vizag +3650 kL Unit 5, Vizag 161 kL Unit 7, Vizag (new site) Unit 2, Vizag +12bn units Unit 4, Vizag +2500 kL Unit 6, Vizag 1478 kL Unit 10, Vizag (new site) LSPL 2, Vizag +550 kL LSPL 4, Vizag +300 kL KRKA JV site, Hyderabad (new site) Site under expansion or construction 10 R&D 1 & Kilo lab, Hyderabad R&D 2, Hyderabad Small Molecules API & FDF LB-1 & LB-2, Bangalore +240 kL LB-4, Vizag +400 kL (new site) CAR-T unit-1, Mumbai +600 treatment CAR-T unit-2, Mumbai +2500 treatment Gene Therapy/ADC, Hyderabad 9000 KL+ API capacity 12 billion + FDF capacity >240 KL Fermentation capacity 1665 Research Scientists R & D Fermentation CGT & ADC 56000 m2 GLP lab facility 6 Research & Development Locations 15 Manufacturing assets High potent Bio-catalysisFlow chemistry Trickle bed hydrogenation Continuous manufacturingSpray drying Peptides Strengthening Development & Manufacturing Capabilities to meet Customer demand Technology platformsADCs Cell & Gene Drug Product >16000 L SPPS capacity
Page 11
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Consistent ESG recognition and Advancing initiatives against SBTi targets 11 SBTi roadmap towards GHG reduction target 2031 • Investments >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites • Making progress on SBTi near term GHG emission targets • Sustainable Procurement code inline with ISO 20400:2017 principles established Scope 1 + 2 Absolute reduction by 42% until FY31 (vs. FY25) Intensity reduction per ₹ by 51.6% until FY31 (vs. FY25) -42% -51.6% Scope 3 S&P Global ESG Score 81/100 Key recognitions for our ESG programs Target Target SCORE 82.6
Page 12
2 Financial Overview Q2 & H1 FY 2027 12
Page 13
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 1H FY27: Sustained strong performance 13 1H FY27 Financial Summary Comments • Revenue : ₹ 4,233 Cr, increased 31% driven by CDMO momentum and healthy growth in Affordable Medicines business • Gross Margins : 62.9%, increased by 330 bps on better divisional mix • R & D spends reported at ₹ 183 Cr* (4.3% of Revenue), increased by 34% due to development efforts toward building Advanced Biologics infrastructure • EBITDA : ₹ 1,406 Cr, increased by 72% • EBITDA Margins : 33.2%, increased 780 bps, due to stronger Revenue growth, higher CDMO revenue and operational leverage • Net Profits : ₹ 809 Cr, increased 126% • OCF driven by higher NWC due to increase of strategic Inventories to ensure supply continuity • Net Debt to EBITDA reduction largely inline • Strong earning growth driving ROCE despite CAPEX acceleration [₹ Crore] 1H FY27 1H FY26 Y-o-Y Revenue 4,233 3,223 31% Gross Margins 62.9% 59.6% 3.3% EBITDA 1,406 818 72% % to Revenue 33.2% 25.4% 7.8% Net Profit 809 358 126% % to Revenue 19.1% 11.1% 8.0% EPS (₹) 15.0 6.6 127% Operating Cash flow 805 1,093 -26% Capex 864 489 77% Net Debt-to-EBITDA 1.0x 1.3x -23% ROCE 22.5% 16.3% +6.2% * Including Capex R&D spends of ₹ 35 Cr towards Advanced Biologics (Gene therapy and ADC)
Page 14
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation [₹ Crore] 1H FY27 1H FY26 Y-o-Y CDMO 1,774 1,040 71% Small molecules 1,710 964 77% Bio 64 76 -16% Affordable Medicines (AM) 2,459 2,183 13% API 1,280 1,254 2% FDF 1,179 929 27% Total Revenue 4,233 3,223 31% ARV Revenue* 1,404 1,380 2% 1H FY27: Accelerating CDMO execution, supported by AM growth 14 * Includes API and Formulation (FDF) combined revenue 1H FY27 Divisional Revenue Performance 1H FY27 Divisional Mix ₹ 4,233 Cr CDMO 42% / +10% over last year Affordable Medicines 58% / -10% over last year 40% 2%30% 28% CDMO - Small molecules Bio API FDF
Page 15
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation [₹ Crore] 1Q FY27 2Q FY27 2Q FY26 Y-o-Y Q-o-Q Revenue 2,026 2,206 1,653 33% 9% Gross Margins 62.7% 63.0% 59.9% +3.1% +0.3% EBITDA 644 762 429 78% 18% % to Revenue 31.8% 34.5% 26.0% +8.5% +2.7% Net Profit 368 441 195 +126% +20% % to Revenue 18.2% 20.0% 11.8% +8.2% +1.8% EPS (₹) 6.8 8.2 3.6 +128% +21% 2Q FY27: Maintaining record momentum across Revenue, EBITDA and Profits 15 2Q FY27 Financial Summary Comments • Revenue : ₹ 2,206 Cr, increased 33% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF) • Gross Margins : 63.0%, increased by 310 bps on better divisional mix • R & D spends reported at ₹ 65 Cr (2.9% of Revenue), decreased by 6% • EBITDA : ₹ 762 Cr, increased by 78% Y/Y • EBITDA Margins : 34.5%, increased 850 bps Y/Y, due to favorable product mix and improving operational leverage • Net Profit : ₹ 441 Cr, increased 126% Y/Y
Page 16
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 2Q FY27: Driven by Solid CDMO performance 16 * Includes API and Formulation (FDF) combined revenue [₹ Crore] 1Q FY27 2Q FY27 2Q FY26 Y-o-Y Q-o-Q CDMO 870 904 518 75% 4% Small molecules 835 875 471 86% 5% Bio 35 29 47 -38% -17% Affordable Medicines (AM) 1,156 1,302 1,135 15% 13% API 654 625 617 1% -4% FDF 502 677 518 31% 35% Total Revenue 2,026 2,206 1,653 33% 9% ARV Revenue* 669 735 733 0.3% 10% 2Q FY27 Divisional Revenue Performance 2Q FY27 Divisional Mix ₹ 2,206 Cr CDMO 41% / +10% over last year Affordable Medicines 59% / -10% over last year 40% 1%28% 31% CDMO - Small molecules Bio API FDF
Page 17
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 1,415 1,720 1,570 1,653 1,778 1,812 2,026 2,206 3Q FY25 4Q FY25 1Q FY26 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27 [₹ Cr] 6.8% 9.7% 12.7% 16.3% 18.5% 17.7% 19.3% 22.5% 3Q FY25 4Q FY25 1Q FY26 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27 3.1x 2.3x 1.8x 1.3x 1.2x 1.3x 1.3x 1.0x 3Q FY25 4Q FY25 1Q FY26 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27 Net Debt-to-EBITDA EBITDA & Gross Profit Margins Revenue [₹ Cr] Net Leverage (Net Debt/ ttM EBITDA)RoCE (ttm EBIT/Capital Employed) Quarterly Performance Summary: Sustained growth momentum 17 GPM OPM 285 477 389 429 485 523 644 762 20.1% 27.7% 24.8% 26.0% 27.3% 28.9% 31.8% 34.5%56.9% 54.5% 59.4% 59.9% 60.9% 61.4% 62.7% 63.0% 0.0% 10. 0% 20. 0% 30. 0% 40. 0% 50. 0% 60. 0% 100 200 300 400 500 600 700 800 900 1000 1100 3Q FY25 4Q FY25 1Q FY26 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27
Page 18
3 Business Review & Strategy Q2 & H1 FY 2027 18
Page 19
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation • Robust business model driving rapid growth; H1 increased +77%, anchored by advancing late-stage clinical projects, commercial API supplies and ramp-up of new assets • Accelerating Capacity: Inaugurated Peptide manufacturing facility ahead of schedule; Total SPPS capacity >16,000L and further expanding to service customer needs. Additionally, multiple large-scale API capacity construction in Vizag ongoing • Elevating client collaboration on complex/new modalities and fully integrated projects (Pre-clinical DS to commercial Drug Product manufacturing ) • CDMO Pipeline continue to expand on high quality molecules and active projects spread across multiple technologies and by indications Comments CDMO – Small molecules: Continuous growth and Accelerating capacities Revenue Growth Y-o-Y ▲ 86% Q-o-Q ▲ 5% 19 [₹ Cr] +77% 964 1710 471 408 524 835 875 1H FY26 1H FY27 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27
Page 20
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Comments • Y/Y variation is due to campaign phasing; however, underlying pipeline momentum remain strong • Increasing longer term strategic relationships with major customers across AOF/CDMO to anchor capacity utilization • Scaling enzymatic technology application across clinical and commercial API projects as part of integrated offering • LB-4 Fermentation manufacturing unit progressing as planned (>400kL) and set to be commissioned by 3QFY27. Advancing on capacity reservations by customers Bio – Underlying pipeline progress remain strong Revenue Growth 20 Y-o-Y ▼ 38% Q-o-Q ▼ 17% [₹ Cr] 76 64 47 43 65 35 29 1H FY26 1H FY27 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27
Page 21
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Y-o-Y ▲ 15% Q-o-Q ▲ 13% [₹ Cr] Affordable Medicines – Steady progress Revenue Growth 21 Comments • Over 13% growth, underpin by continued order uptick, consistent volume and pricing resilience across broader ARV and US portfolio • Continued resourcing in line with market needs. Potential new launches/integrated CMO engagements and ramping product registration across EM driving healthy outlook • Sustaining reliable delivery execution amidst global volatility • KRKA JV update: FDF site progress on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability • Filings update: DMF filings - Cumulatively, 92 filed till date. Developed market FDF filings - 2 dossiers filed and 2 approvals received in H1. Cumulatively, 96 products filed till date Global FDF filings US EU Canada ROW Approved 39* 19 16 59 Pending 12 3 7 10 Total 51 22 23 69 API FDF * Includes 15 Tentative approvals in US +13% 929 1179 518 607 451 502 677 1254 1280 617 720 772 654 625 2183 2459 1135 1327 1223 1156 1302 1H FY26 1H FY27 2Q FY26 3Q FY26 4Q FY26 1Q FY27 2Q FY27
Page 22
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation 22 Advanced Biologics – Key Updates Gene Therapy & Anti body Drug Conjugates (ADCs) Facility under construction – Qualification expected by end 2027 • Commissioning and operational readiness of GMP manufacturing facility on track with focus on integrated offering (PD, Conjugation and Fill-finish capabilities) • Expanding CDMO opportunities for future growth • Technology transfer of the acquired ADC programs from Aarvik Therapeutics progressing as planned • Gram-to-Multi-Kg scale to support clinical/commercial supplies Cell Therapy • Continued progress >750 infusions as on Sep 2026 • Gradual ramp-up of the 2nd GMP facility released in March 2026 (capacity to produce +2,500 treatment) • BCMA Ph-1 trails concluded and initiated Ph-2 studies Priorities NexCar19 commercial acceleration Expanding Portfolio pipeline Global partnerships & Licensing upside
Page 23
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Highest standard of Quality & Compliance - Commitment to “One Quality for all Markets” Key Facilities Key Regulatory Certifications Date # audits (since inception) EIR Status Kilo Lab – R&D USFDA, TGA, KFDA, PMDA, ANVISA - Brazil 2024 5 Unit 1 USFDA, TGA, MHRA, WHO-Geneva, PMDA, ANVISA 2024 7 Unit 2 USFDA, WHO-Geneva, EMA 2023 5 Unit 3 USFDA, WHO-Geneva, JAZMP-Slovenia, ANVISA 2024 5 Unit 4 WHO-Geneva, USFDA 2025 2 Unit 5 USFDA 2022 1 Unit 6 USFDA 2018 1 Last US FDA inspection 23 Quality audits & Inspection by Global Customers, Regulators since inception 1460+ Successful Inspections by major Regulators (US FDA, WHO, EU EMA, and Japan PMDA) 54 H1 FY27 update • 59 Quality audit in H1: Regulatory # 1 & Customer # 58 • On-going improvement in QMS and implementation across different functions, incl. R&D, Quality and Technical operations • On going digitization. LIMS implemented Unit-04 and is planned for rollout across additional sites
Page 24
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Click below to Express Join with Diamond Pass Click here to register Laurus Labs Results Conference Call to be held on Thursday, 29 October 2026 at 5:00 PM IST Earnings call details Dial – In – Details Universal Dial-In +91 22 6280 1384 India Local access Number +91 22 7115 8285 Singapore +800 1012045 Hong Kong +800 964448 USA +1 866 746 2133 UK +0808 101 1573 24
Page 25
© 2026 Laurus Labs Ltd. 29/10/2026Q2 & H1 - FY27 Results Presentation Investor relations Vivek Kumar T: +914066594366 E: investorrelations@lauruslabs.com E: vivek.k@lauruslabs.com For more information Please visit our website www.lauruslabs.com Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions. The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence. Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices. Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518. Please consider the environment before printing this Presentation Additional Information 25